Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Torrent Pharma makes and sells generic medicines for the heart, brain, gut, and other common conditions, mostly in India and a few other countries.
Torrent Pharma is a maker of generic medicines. It sells pills and tablets that treat everyday chronic problems — blood pressure and heart conditions, brain and nerve issues, stomach and gut trouble — plus a range of other therapies. It sells mostly in India, where it is a well-known brand in doctors' clinics and pharmacies, and it also sells in markets abroad like Brazil and the United States.
The business works like most generic drugmakers. Torrent copies medicines whose patents have expired, gets them approved by regulators, and sells them at prices far below the original brand. Customers are patients, but the real buyers are doctors who write the prescriptions and pharmacies that stock the shelves. In India, Torrent's big edge is its sales force: thousands of representatives visit doctors every day to get its brands prescribed. That personal, on-the-ground selling is expensive but hard for rivals to copy, and it is why Torrent earns healthy margins in its home market. Outside India, the story is different. In Brazil and the US, Torrent competes on price against much larger generic makers, so those markets bring in revenue but thinner profits. The company has also spent heavily on buying brands and businesses over the years, plus building new plants, which loaded it with debt. Paying that debt down has been a real focus.
A few things matter for its future. India's chronic-disease medicine market keeps growing as the population ages, which suits Torrent's portfolio well. Its spending on research and on factory upgrades is aimed at winning more complex products and passing tougher inspections. And the balance sheet is the swing factor: less debt means more freedom to invest or return cash to shareholders.
Saved answer · last researched 12 Nov 2026